Use of iodine 131I-tositumomab radioimmunotherapy in a patient with Waldenstrom's macroglobulinemia |
| |
| Authors: | Tsai Donald E Maillard Ivan Downs Lisa H Alavi Abass Nasta Sunita D Glatstein Eli Schuster Stephen J |
| |
| Affiliation: | a Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USAb Division of Nuclear Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USAc Department of Radiation Oncology, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA |
| |
| Abstract: | Waldenstrom's macroglobulinemia is an indolent B-cell malignancy that is characterized by high levels of IgM paraprotein production and is incurable with standard chemotherapy. Iodine 131I-Tositumomab (iodine-131-labeled murine anti-CD20 monoclonal antibody; Bexxar) is a novel radioimmunotherapeutic agent that has a high response rate in relapsed or chemotherapy refractory, CD20-positive, low grade or transformed B-cell non-Hodgkin's lymphomas. There are no data on the use of radioimmunotherapy in Waldenstrom's macroglobulinemia. We report a patient with Waldenstrom's macroglobulinemia with transformation to a large B-cell lymphoma, who was treated successfully with iodine 131I-tositumomab. The patient had a complete response to the treatment, including disappearance of any detectable IgM paraprotein. This case report demonstrates the potential for radioimmunotherapy in CD20 positive B-cell malignancies. |
| |
| Keywords: | Tositumomab Waldenstrom's macroglobulinemia Radioimmunotherapy Monoclonal antibody |
| 本文献已被 InformaWorld PubMed 等数据库收录！ |
|
